No Data
Vista Outdoor Reiterated FY25 Sales Of $2.665B-$2.775B Vs $2.74B Est, Discloses Q1 Sales Guide Of $272M-$276M Vs $674M Est
Reaffirms Outlook for Fiscal Year 2025The Company reaffirms its guidance for Fiscal Year 2025 for Vista Outdoor, as well as The Kinetic Group and Revelyst. The Company expects the following results
Vista Outdoor Increases Purchase Price in CSG Merger Agreement By $50M to $2.15B
The amended merger agreement with CSG further increases the base purchase price payable by CSG for the acquisition of The Kinetic Group business (the "CSG Transaction") by $50 million to $2.15
Needham Initiates Coverage On Neumora Therapeutics With Buy Rating, Announces Price Target of $23
Needham analyst Ami Fadia initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Buy rating and announces Price Target of $23.
Neumora Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 112.77% Needham → $23 Initiates Coverage On → Buy 07/08/2024 85.01% Mizuho → $20 Initiates
Chuy's Holdings Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 1.13% Wedbush $38 → $37.5 Downgrades Outperform → Neutral 07/19/2024 1.13% Stephens & Co. $36 →
Keefe, Bruyette & Woods Downgrades Mr. Cooper Gr to Market Perform, Maintains Price Target to $95
Keefe, Bruyette & Woods analyst Bose George downgrades Mr. Cooper Gr (NASDAQ:COOP) from Outperform to Market Perform and maintains the price target from $95 to $95.